Beta Bionics Q3 2026 net loss widens 71% year over year to $24.35 million; Q3 2026 net sales rise 30% to $35.51 million year over year

PUBT · 1d ago
Beta Bionics Q3 2026 net loss widens 71% year over year to $24.35 million; Q3 2026 net sales rise 30% to $35.51 million year over year
  • Beta Bionics’ third-quarter 2026 net loss widened 71% year over year to $24.35 million.
  • Net sales rose 30% year over year to $35.5 million, while PBP channel net sales more than doubled to $13.6 million.
  • FDA-cleared Mint is expected to launch commercially across the U.S. in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610271602PRIMZONEFULLFEED9853632) on October 27, 2026, and is solely responsible for the information contained therein.